PRRT2 and atherosclerosis: To identify the key PKC isoforms involved in the pathogenesis and to determine whether the combinations of isoform-specific inhibitors might have synergistic effects in the treatment of diabetes-associated atherosclerosis are two potential challenges in developing therapeutic agents targeting PKC for ASCVD.